{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "mesh:D002470",
      "entity_text" : "cell survival",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P01236",
      "entity_text" : "PRL",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "It has been shown that PRL variants acting as competitive PRLR antagonists can efficiently downregulate PRLR signaling, cell survival, and/or proliferation in various breast or prostate cancer preclinical assays.",
  "reading_complete" : "2020-08-04T10:53:10Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:52:14Z",
  "trigger" : "downregulate",
  "evidence" : [ "PRL variants acting as competitive PRLR antagonists can efficiently downregulate PRLR signaling, cell survival" ],
  "pmc_id" : "5481306",
  "score" : 0
}